{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rifaximin+%28Xifaxan%29",
    "query": {
      "intervention": "Rifaximin (Xifaxan)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 79,
    "total_pages": 8,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rifaximin+%28Xifaxan%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T19:05:49.536Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01866826",
      "title": "Rifaximin for Chronic Immune Activation in People With HIV",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "Rifaximin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2013-01-18",
      "completion_date": "2018-02-28",
      "has_results": true,
      "last_update_posted_date": "2020-02-26",
      "last_synced_at": "2026-10-02T19:05:49.536Z",
      "location_count": 3,
      "location_summary": "Bethesda, Maryland • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01866826"
    },
    {
      "nct_id": "NCT00281502",
      "title": "The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatic Encephalopathy",
        "Hepatitis C",
        "Liver Cirrhosis"
      ],
      "interventions": [
        {
          "name": "Rifaximin (drug)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 50,
      "start_date": "2005-12",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2010-11-05",
      "last_synced_at": "2026-10-02T19:05:49.536Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00281502"
    },
    {
      "nct_id": "NCT06312683",
      "title": "Rifaximin for the Secondary Prevention of Recurrent Pouchitis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pouchitis"
      ],
      "interventions": [
        {
          "name": "Rifaximin 550 MG Oral Tablet [XIFAXAN]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 16,
      "start_date": "2024-07-01",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-10-02T19:05:49.536Z",
      "location_count": 2,
      "location_summary": "New York, New York • Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06312683"
    },
    {
      "nct_id": "NCT06727422",
      "title": "Efficacy of Rifaximin With NAC in IBS-D",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "IBS (Irritable Bowel Syndrome)",
        "IBS-D (Diarrhea-predominant)"
      ],
      "interventions": [
        {
          "name": "rifaximin 66mg + N-acetylcysteine 560mg three times daily",
          "type": "DRUG"
        },
        {
          "name": "RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mark Pimentel, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 225,
      "start_date": "2026-02-04",
      "completion_date": "2027-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-20",
      "last_synced_at": "2026-10-02T19:05:49.536Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06727422"
    },
    {
      "nct_id": "NCT01359228",
      "title": "Rifaximin Treatment of Papulopustular Rosacea",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rosacea"
      ],
      "interventions": [
        {
          "name": "Rifaximin (XIFAXAN)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2013-04",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2014-04-28",
      "last_synced_at": "2026-10-02T19:05:49.536Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01359228"
    },
    {
      "nct_id": "NCT01543178",
      "title": "Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Irritable Bowel Syndrome With Diarrhea"
      ],
      "interventions": [
        {
          "name": "open-label rifaximin",
          "type": "DRUG"
        },
        {
          "name": "double-blind placebo",
          "type": "DRUG"
        },
        {
          "name": "double-blind rifaximin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch Health Americas, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2583,
      "start_date": "2012-02",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2017-12-12",
      "last_synced_at": "2026-10-02T19:05:49.536Z",
      "location_count": 293,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Dothan, Alabama + 226 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01543178"
    },
    {
      "nct_id": "NCT01842113",
      "title": "Quality of Life and Nutritional Improvements in Cirrhotic Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Liver Cirrhosis",
        "Hepatic Encephalopathy",
        "Portal Hypertension"
      ],
      "interventions": [
        {
          "name": "Rifaximin",
          "type": "DRUG"
        },
        {
          "name": "Lactulose",
          "type": "DRUG"
        },
        {
          "name": "Lactulose Placebo",
          "type": "DRUG"
        },
        {
          "name": "Rifaximin Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tampa General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2013-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-09-23",
      "last_synced_at": "2026-10-02T19:05:49.536Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01842113"
    },
    {
      "nct_id": "NCT01695174",
      "title": "A Pilot Study of Xifaxan to Treat Patients With PSC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Primary Sclerosing Cholangitis (PSC)"
      ],
      "interventions": [
        {
          "name": "Xifaxan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 16,
      "start_date": "2012-08",
      "completion_date": "2014-03",
      "has_results": false,
      "last_update_posted_date": "2014-10-15",
      "last_synced_at": "2026-10-02T19:05:49.536Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01695174"
    },
    {
      "nct_id": "NCT02498418",
      "title": "Study Comparing Rifaximin With Xifaxan 200 mg in Traveler's Diarrhea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diarrhea"
      ],
      "interventions": [
        {
          "name": "Rifaximin",
          "type": "DRUG"
        },
        {
          "name": "Xifaxan®",
          "type": "DRUG"
        },
        {
          "name": "Placebo Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 739,
      "start_date": "2016-01-06",
      "completion_date": "2017-02-28",
      "has_results": true,
      "last_update_posted_date": "2019-12-05",
      "last_synced_at": "2026-10-02T19:05:49.536Z",
      "location_count": 1,
      "location_summary": "Coral Gables, Florida",
      "locations": [
        {
          "city": "Coral Gables",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02498418"
    },
    {
      "nct_id": "NCT00533910",
      "title": "Rifaximin in Minimal Hepatic Encephalopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hepatic Encephalopathy"
      ],
      "interventions": [
        {
          "name": "Rifaximin",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hunter Holmes Mcguire Veteran Affairs Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 42,
      "start_date": "2007-10",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2020-12-17",
      "last_synced_at": "2026-10-02T19:05:49.536Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00533910"
    }
  ]
}